BCP for urinary tract infections (UTIs) due to its antibacterial and analgesic effects.

Beta-caryophyllene is a natural compound that has been shown to reduce inflammation in various health conditions, including a painful bladder condition called interstitial cystitis which led them to study its effects on urinary tract infections (UTIs). In mice, treatment with beta-caryophyllene significantly reduced the amount of bacteria in the urine and bladder after 24 hours. It also improved their behavior and showed less inflammation in the bladder. 
• Beta-caryophyllene (beta-C) activates the cannabinoid type 2 receptor (CB2R) and exhibits anti-inflammatory properties.
• The study used a standard model of UTI, inoculating female mice with uropathogenic Escherichia coli.
• Treatment groups included beta-C (100mg/kg IP), fosfomycin (an antibiotic), and combination therapy.
• Antibacterial: Significant reduction in bacterial burden 24 hours post-treatment with beta-C similar to antibacterial to low-dose fosfomycin.
• Anti-inflammatory: beta-C treatment significantly reduced behavioral changes indicating pain > > fosfomycin, unrelated to CB2R activation.
• beta-C decrease in the number of adherent leukocytes, improved capillaries and red blood cell velocity. 
•  Combination of Beta-C with fosfomycin produced no advantages

​COMMENT: BCP showed remarkable dual action in regulating pain and infection without the need for additional antibiotics. The dose of 100mg/kg was a common oral or injection standard for most trials but with an equivalent of about 7mg/kg in humans. But with enhanced bioavailability of liposomes at approximately 10x equates to .7 x 70kg= 49mg which is well within the standard liposome dosing protocol.

Antibacterial and Analgesic Properties of Beta-Caryophyllene in a Murine Urinary Tract Infection Model. https://doi.org/10.3390/molecules28104144